Introduction
============

Lyme disease (LD) is a multisystem inflammatory, tick-borne disease resulting from infection with *Borrelia burgdorferi* ([@b1-mmr-17-04-4953],[@b2-mmr-17-04-4953]). LD is present in \>80 countries, including China. A total of \~3,000,000 cases of LD are reported each year worldwide, representing an incidence of \~0.111% ([@b2-mmr-17-04-4953],[@b3-mmr-17-04-4953]). LD seriously affects human health, in addition to economic development. As a result, this widespread disease has been given attention regarding its prevention and treatment by the World Health Organization ([@b3-mmr-17-04-4953]). Lyme neuroborreliosis (LNB) is a principal manifestation of LD and is caused by the inflammatory effects of the spirochete *B. burgdorferi* on the nervous system. LNB causes extensive neurological damage and encephalitic memory impairment, even leading to dementia and personality disorders. Given the high disability rate caused by the disease, researchers and clinicians are giving more concentrated attention to LNB ([@b4-mmr-17-04-4953],[@b5-mmr-17-04-4953]); however, its pathogenesis remains incompletely understood. It is generally accepted that LNB is caused by an autoimmune response triggered by molecular mimicry ([@b6-mmr-17-04-4953],[@b7-mmr-17-04-4953]).

Microglial cells, the resident macrophage cells within the central nervous system (CNS), are important in initiating an immune response to microbial products ([@b8-mmr-17-04-4953]). As a previous study demonstrated, CNS damage and inflammation may activate microglia ([@b9-mmr-17-04-4953]). Reactive microglia produce various cytokines and chemokines causing an acute inflammatory reaction, which leads to neuronal damage and apoptosis. Microglia cells are hypersensitive to CNS damage. These cells multiply rapidly, begin to express major histocompatibility complex proteins, migrate and subsequently differentiate into phagocytes that secrete cytokines and other toxic substances ([@b10-mmr-17-04-4953],[@b11-mmr-17-04-4953]).

Previous studies have suggested that *B. burgdorferi* basic membrane protein A (BmpA), one of the primary *B. burgdorferi* pathogenic substances, exhibits a potent pro-inflammatory effect ([@b11-mmr-17-04-4953]--[@b13-mmr-17-04-4953]). In the authors\' previous study, an *Escherichia coli* expression system was established and purified recombinant BmpA (rBmpA) was successfully obtained. When stimulated with rBmpA, murine microglia BV2 cells produced pro-inflammatory chemokines, including C-X-C motif chemokine 2 (CXCL2), C-C motif chemokine (CCL) 5 and CCL22, causing inflammation and damage in mice ([@b13-mmr-17-04-4953]). However, the signal transduction mechanism involved is unclear ([@b13-mmr-17-04-4953]).

The nuclear factor κ-B (NF-κB) is A protein complex which was found to specifically bind to the κB sequence (GGGACTTTCC) of the immunoglobulin K enhancer and regulated the expression of target genes ([@b14-mmr-17-04-4953]--[@b16-mmr-17-04-4953]). NF-κB has received widespread interest from researchers for its crucial role in the immune system. It has been demonstrated in unstimulated cells that inhibitor of NF-κB (IκB-β) combines with NF-κB and maintains NF-κB an inactive state. The stimuli that cause NF-κB activation target IκB-β for degradation via a phosphorylation-dependent ubiquitination process ([@b16-mmr-17-04-4953],[@b17-mmr-17-04-4953]). With the degradation of IκB-β, NF-κB is activated, entering the cell nucleus where it encounters a promoter with DNA binding sites for NF-κB ([@b17-mmr-17-04-4953],[@b18-mmr-17-04-4953]). The activation of target gene transcription induces the expression of specific mRNAs, and the production of cytokines and chemokines, thereby regulating the activation, multiplication, infiltration, chemotaxis and secretion of immune cells ([@b18-mmr-17-04-4953]--[@b20-mmr-17-04-4953]). As rBmpA stimulates the production of CXCL and CCL chemokines in microglia, it was hypothesized that NF-κB may be closely associated with rBmpA-induced chemokine production in BV2 cells ([@b13-mmr-17-04-4953]).

Based on the conclusions of the authors\' previous study demonstrating that rBmpA stimulates the production of inflammatory chemokines in BV2 cells, the present study continued to investigate the signal transduction mechanism of LNB ([@b13-mmr-17-04-4953]). Additionally, the present study investigated the role of NF-κB in the signaling pathway of rBmpA-induced inflammatory chemokines and provides a scientific basis for the prevention and treatment of LBN.

Materials and methods
=====================

### rBmpA preparation

Recombinant BmpA proteins were produced in *E. coli* using the bacterial expression vector pGEX-6P1 (GE Healthcare, Chicago, IL, USA). Expression, purification and enzymatic cleavage of the glutathione S-transferase fusion proteins were performed as previously described ([@b14-mmr-17-04-4953],[@b15-mmr-17-04-4953]).

### Cell culture and groups

BV2 cells (Kunming Medical University Biological Engineer Center, Kunming, China) were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM)/high glucose with 5% cattle serum (CS; HyClone, Logan, UT, USA), 1% penicillin/streptomycin (Sangon Biotech Co., Ltd., Shanghai, China) at 37°C with 5% CO~2~. BV2 cells were seeded into a 6-well plate at a concentration of 3×10^5^ cells/ml. Supernatants were discarded until the cells fully adhered to the plate. Cells were divided into three groups (negative control group, positive control group and experimental group), and were stimulated with 2 ml/well PBS with 5% CS-DMEM medium, 1 µg/ml lipopolysaccharide (LPS; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), and 20 µg/ml rBmpA, respectively. Radioimmunoprecipitation assay buffer (high; Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) was used to lyse the cells and cell lysates were collected at 12, 24 and 48 h following stimulation.

### ELISA analysis

Culture supernatants were collected at 6, 12 and 24 h following stimulation with rBmpA and were analyzed by ELISA. Mouse CXCL2 (MIP-2), mouse CCL22 (MDC) and mouse CCL5 (RANTES) ELISA kits (RayBiotech, Inc., Norcross, GA, USA; cat. nos. P10889, O88430 and P30882) was used following manufacturer\'s protocol. A Bio-Rad microplate reader (Model 680; Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used to measure the absorbance at 450 nm.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis

Harvested cells were lysed with RNAiso Plus (Takara Biotechnology Co., Ltd., Dalian, China) and RNA was extracted, following the manufacturer\'s protocol. Total RNA was reverse transcribed to cDNA. The RT-qPCR was performed using the real-time PCR System Cfx-Connect (Bio-Rad Laboratories, Inc.). The reaction conditions of the RT-qPCR were as follows: Denaturation at 95°C for 30 min, annealing at 58°C for 1 h and extension at 65°C for 5 sec. The total volume used in the PCR was 25 µl, including 2 µl cDNA, 12.5 µl SYBR (Takara Biotechnology, Co., Ltd.), 8.5 µl dH~2~O, 1 µl forward primer and 1 µl reverse primer (Tsingke Biotech Co., Ltd., Kunming, China). The sequences of the specific primers used to amplify NF-κB p65 and GAPDH were as follows: NF-κB p65 forward, 5′-GCTACACAGAGGCCATTGAA-3′ and reverse, 5′-TCCCGGAGTTCATCTATGTG-3′; IκB-β forward, 5′-GGGAACGTCAGTCTGTACCA-3′ and reverse, 5′-GCACCATCGCTCTCTGTTTT-3′; GAPDH forward, 5′-TCCCAGAGCTGAACGGGAAG-3′ and reverse, 5′-TCAGTGGGCCCTCAGATGC-3′. The gene expression level was calculated using the method of 2^−ΔΔCq^ ([@b21-mmr-17-04-4953]--[@b23-mmr-17-04-4953]).

### Western blot analysis

Total protein quantitation analysis was used as the internal control for quantitative fluorescent western blot analysis ([@b24-mmr-17-04-4953]--[@b27-mmr-17-04-4953]). Cells were lysed in radioimmunoprecipitation lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) with 1 mM phenylmethylsulfonyl fluoride (Beyotime Institute of Biotechnology), and quantified using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology). Proteins were separated on 10% TGX FastCast acrylamide gels (Bio-Rad Laboratories, Inc.) with a loading mass of 20 µg total protein, then subsequently transferred to a polyvinylidene difluoride (PVDF) membranes (0.2 µm; Bio-Rad Laboratories, Inc.) using Trans-Blot Turbo Transfer System (p65, 15 V in 4-min protocol; IκB-β, 15 V in 4-min protocol; Bio-Rad Laboratories, Inc.) with Trans-Blot Turbo Midi Transfer Packs (Bio-Rad Laboratories, Inc.). The PVDF membranes were blocked with 5% skim milk at 37°C for 2 h. Blots were incubated with specific primary antibodies of NF-κB p65 (cat. no. ab16502; 1:2,000; Abcam, Cambridge, UK) or IκB-β (cat. no. ab7574; 1:1,000; Abcam) overnight at 4°C, and subsequently incubated with goat anti-rabbit secondary antibodies (cat. no. BS13278; p65 1:10,000; Nanjing Bioworld Biotech Co., Ltd., Nanjing, China; cat. no. ab150077; IκB-β; 1:3,000; Abcam) at room temperature for 2 h. The blots were washed three times between the primary and secondary antibody incubations. The immunoreactive bands were imaged using an infrared imaging system (Bio-Rad Laboratories, Inc.). ChemiDoc^™^ XRS+Systems with Image Lab^™^ software (Bio-Rad Laboratories, Inc.) was used to analyze the western blot results of NF-κB p65 and IκB-β.

### Statistical analysis

The results are expressed as the mean ± standard error of the mean and were analyzed using the GraphPad Prism 6 software package (GraphPad Software, Inc., La Jolla, CA, USA) ([@b26-mmr-17-04-4953]). Two-way analysis of variance was used to calculate the P-values, multiple comparison between the groups was performed using the Student-Newman-Keuls method. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### rBmpA significantly stimulates the production of the inflammatory cytokines CXCL2, CCL5 and CCL22 in BV2 cells

To determine whether rBmpA induces the production of pro-inflammatory chemokines in BV2 cells, analysis of CXCL2, CCL5 and CCL22 concentrations in the cell supernatants was assayed by ELISA. The results demonstrated that rBmpA significantly increased CXCL2, CCL5 and CCL22 expression at all time points tested compared with the PBS only group (P\<0.05; [Fig. 1](#f1-mmr-17-04-4953){ref-type="fig"}). The expression of the three chemokines demonstrated an increasing trend between 12 and 48 h, except for a slight decline in CCL5 between 24 and 48 h ([Fig. 1B](#f1-mmr-17-04-4953){ref-type="fig"}).

### rBmpA stimulation induces an increase in NF-κB and decrease in IκB-bmRNA in BV2 cells

rBmpA stimulation significantly increased CXCL2, CCL5 and CCL22 expression compared with the PBS control (P\<0.05). Therefore, the rBmpA-induced nuclear translocation of NF-κB p65 and degradation of cytosolic IκB-β was investigated. RT-qPCR was used to analyze the expression of NF-κB p65 and IκB-β mRNA. As exhibited in [Fig. 2](#f2-mmr-17-04-4953){ref-type="fig"}, the expression of NF-κB mRNA in the group treated with rBmpA was significantly increased (P\<0.01) compared with the PBS-only control at 12, 24 and 48 h and rBmpA treatment significantly decreased the intracellular levels of IκB-β (P\<0.05).

### rBmpA stimulation induces an increase in NF-κB p65 and the degradation of IκB-bproteins in BV2 cells

Western blot analysis was used to detect the protein expression levels of NF-κB p65 and IκB-β in BV2 cells. As exhibited in [Fig. 3](#f3-mmr-17-04-4953){ref-type="fig"}, following stimulation with rBmpA for 12, 24 and 48 h, NF-κB p65 protein expression was significantly increased (P\<0.05) and the protein level of IκB-β was significantly decreased (P\<0.05) in the rBmpA treatment group compared with the PBS-only control. Increased expression levels of NF-κB p65 protein were observed in the rBmpA and LPS treatment groups. rBmpA significantly decreased the intracellular levels of IκB-β protein compared with the PBS control (P\<0.05).

Discussion
==========

NF-κB is a nuclear transcription factor which regulates the immune response, stress response and apoptosis ([@b28-mmr-17-04-4953]). Upregulation of NF-κB has been demonstrated in various tumors, pulmonary disease and hepatic disease. Previous *in vitro* studies have suggested that NF-κB is a key signal transduction molecule in the downstream pathway of Toll-like receptors (TLRs) ([@b29-mmr-17-04-4953],[@b30-mmr-17-04-4953]). Once the TLRs are stimulated by various pathogenic factors, the degradation of IκB-β is initiated and NF-κB is free to enter the cell nucleus, where NF-κB combines with the IκB motif controlling the transcription of a number of cytokines, including tumor necrosis factor-α (TNF-α), CXCL13 and interleukin (IL)-6. Studies have demonstrated that NF-κB is a transducer of various common inflammatory signaling pathway reactions ([@b27-mmr-17-04-4953]--[@b30-mmr-17-04-4953]). Therefore, methods of inhibiting NF-κB signaling have potential therapeutic applications in inflammatory diseases. At present, a number of anti-inflammatory drugs and anti-rheumatic drugs, including corticosteroids and aspirin, have been confirmed to be inhibitors of NF-κB activation ([@b31-mmr-17-04-4953],[@b32-mmr-17-04-4953]).

It has been reported that the *B. burgdorferi bmpA/B* gene operon exhibits the most marked upregulation in mouse and human joints ([@b33-mmr-17-04-4953]). BmpA possesses stimulatory activity through functional domains that trigger the inflammatory response. For example, the activated NF-κB kinase signalling pathway in articular synovial cells was demonstrated to produce pro-inflammatory cytokines including TNF-α and IL-1β, triggering prostaglandin E2 receptor EP4 subtype (PGE-2) ([@b15-mmr-17-04-4953],[@b34-mmr-17-04-4953]). Rasley *et al* ([@b35-mmr-17-04-4953]) confirmed that *B. burgdorferi* was an important stimulus that induced microglia to produce IL-6, TNF-α and PGE-2, which was associated with increased expression of NF-κB, TLR2 and cluster of differentiation 14 in BV2 cells. By activating signaling molecules, *B. burgdorferi* stimulated immune cells to produce multiple inflammatory substances ([@b35-mmr-17-04-4953]). Further investigation by Sun *et al* ([@b36-mmr-17-04-4953]) suggested that substance P was able to prompt *B. burgdorferi*-induced NF-κB activation by upregulating NF-κB subunit p65, causing a significant increase in the production of inflammatory cytokines ([@b36-mmr-17-04-4953]). NF-κB serves an important role in the inflammatory cytokine signaling pathway of immune cells. However, rBmpA and NF-κB associated pathogenesis in LNB, to the best of the authors\' knowledge, has not been reported in the literature. A recent report indicated that rBmpA induced activation of BV2 cells with a concentration-dependent secretion of inflammatory chemokines ([@b13-mmr-17-04-4953]). Therefore, rBmpA may be associated with the inflammatory chemokines produced by BV2 cells and the occurrence of LNB. However, the precise mechanism of the signal transduction pathway remains uncertain.

In the present study, whether NF-κB was a key modulator in the inflammatory chemokines (CXCL2, CCL5 and CCL22) signaling pathway stimulated by rBmpA in BV2 cells was investigated. The results of the present study demonstrated that CXCL2, CCL5, CCL22, NF-κB mRNA and NF-κB protein increased and the protein and mRNA levels of IκB-β decreased following stimulation with rBmpA in BV2 cells. It was demonstrated that NF-κB served a key role in the signaling pathways stimulated by rBmpA in BV2 cells, resulting in the production of various inflammatory chemokines. This result increases the understanding of the pathogenesis of LNB. Future studies will investigate the key proteins in inflammatory chemokine signaling pathways stimulated by rBmpA and, most importantly, investigate whether these signaling pathways also modulate the pathogenesis of Lyme arthritis, dermatitis and carditis. The long-term aim is to investigate whether preventive and therapeutic medicines for LNB may be developed that target these proteins ([@b37-mmr-17-04-4953]).

In conclusion, following stimulation by rBmpA, BV2 cells overexpressed NF-κB and exhibited significantly reduced expression of IκB-β in the inflammatory cytokine-signaling pathway. This result suggested that NF-κB is important in the inflammatory cytokines signaling pathways stimulated by rBmpA and may be associated with the occurrence of LNB. The present study further clarified the mechanism underlying the rBmpA-induced inflammatory chemokines signaling pathway in microglial cells, and provides a scientific basis for the prevention and treatment of LNB.
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![Analysis of the expression of inflammatory cytokines in BV2 cells. (A) CXCL2, (B) CCL5 and (C) CCL22 expression following stimulation with 20 µg/ml rBmpA for different time periods (12, 24 and 48 h). The experimental results exhibited are representative of three independent tests. Each value represents the mean ± standard error of the mean. \*P\<0.05; \*\*P\<0.01. rBmpA, recombinant basic membrane protein A; LPS, lipopolysaccharide; CXCL2, C-X-C motif chemokine 2; CCL, C-C motif chemokine.](MMR-17-04-4953-g00){#f1-mmr-17-04-4953}

![Time-dependent effects of rBmpA on the expression of NF-κB p65 and IκB-β mRNA at 12--24 h. BV2 microglia were stimulated by 20 mg/ml rBmpA for 48 h. The levels of (A) NF-κB p65 and (B) IκB-β mRNA were determined by reverse transcription-quantitative polymerase chain reaction. Each value represents the mean ± standard error of the mean. n=3. \*P\<0.05; \*\*P\<0.01. NF-κB, nuclear factor κ-B; rBmpA, recombinant basic membrane protein A; IκB-β. inhibitor of NF-κB; LPS, lipopolysaccharide.](MMR-17-04-4953-g01){#f2-mmr-17-04-4953}

![Total protein quantification was used to analyze the protein expression of NF-κB p65 and IκB-β in BV2 cells. The cells were stimulated with 20 µg/ml rBmpA or 1 µg/ml LPS at different time points (12, 24 and 48 h). (A) The total protein was measured by SDS-PAGE using a Stain-Free Gel. The expression of (B) NF-κB p65 and (C) IκB-β, exhibited as the mean ± standard error of the mean. n=3. \*P\<0.05; \*\*P\<0.01. NF-κB, nuclear factor κ-B; rBmpA, recombinant basic membrane protein A; IκB-β inhibitor of NF-κB; LPS, lipopolysaccharide.](MMR-17-04-4953-g02){#f3-mmr-17-04-4953}
